r-hLIF for Improving Embryo Implantation in IVF
This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.
Infertility, Implantation Failure.
Drug: Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomised, Double-blind, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Acceptability of r-hLIF for Improving Embryo Implantation Following in Vitro Fertilisation (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure.|
- Improvement of embryo implantation and Safety [ Time Frame: Various ]
- Secondary endpoints were implantation rate, proportion of patients with biochemical pregnancy and the number of live births. [ Time Frame: various ]
|Study Start Date:||September 2001|
|Study Completion Date:||April 2002|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00504530
|Principal Investigator:||Peter Brinsden, M.D.||Bourn Hall Clinic, Bourn Hall, High Street, Bourn, Cambridge CB3 7TR|